Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients ; volume:12 ; number:3 ; year:2018 ; pages:608-616
Case reports in gastroenterology ; 12, Heft 3 (2018), 608-616

Urheber
Silva, Elen Farinelli de Campos
Baima, Júlio Pinheiro
de Barros, Jaqueline Ribeiro
Renosto, Fernanda Lofiego
de Sibia, Carina de Fatima
Saad-Hossne, Rogério
Sassaki, Ligia Yukie

DOI
10.1159/000493921
URN
urn:nbn:de:101:1-2019012323210427597475
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:55 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Silva, Elen Farinelli de Campos
  • Baima, Júlio Pinheiro
  • de Barros, Jaqueline Ribeiro
  • Renosto, Fernanda Lofiego
  • de Sibia, Carina de Fatima
  • Saad-Hossne, Rogério
  • Sassaki, Ligia Yukie

Ähnliche Objekte (12)

Review of local injection of anti-TNF for perianal fistulising Crohn’s disease

Review of local injection of anti-TNF for perianal fistulising Crohn’s disease

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros

Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review

Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients

Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients

Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease

Analysis of the factors related to anti-TNF alpha response in the treatment of Crohn's Disease

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease

Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial

Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers

Crohn’s appendicitis

Crohn’s appendicitis

Monitoring of anti-TNF biological treatments

Monitoring of anti-TNF biological treatments

Verbundene Objekte